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Preterm birth (PTB) is a leading global cause of infant mortality. Risk factors include genetics,
lifestyle choices and infection. Understanding the mechanism of PTB could aid the devel-
opment of novel approaches to prevent PTB. This study aimed to investigate the metabolic
biomarkers of PTB in early pregnancy and the association of significant metabolites with par-
ticipant genotypes. Maternal sera collected at 16 and 20 weeks of gestation, from women
who previously experienced PTB (high-risk) and women who did not (low-risk controls), were
analysed using 1H nuclear magnetic resonance (NMR) metabolomics and genome-wide
screening microarray. ANOVA and probabilistic neural network (PNN) modelling were per-
formed on the spectral bins. Metabolomics genome-wide association (MGWAS) of the spec-
tral bins and genotype data from the same participants was applied to determine potential
metabolite-gene pathways. Phenylalanine, acetate and lactate metabolite differences be-
tween PTB cases and controls were obtained by ANOVA and PNN showed strong predic-
tion at week 20 (AUC = 0.89). MGWAS identified several metabolite bins with strong genetic
associations. Cis-eQTL analysis highlighted TRAF1 (involved in the inflammatory pathway)
local to a non-coding SNP associated with lactate at week 20 of gestation. MGWAS of a
well-defined cohort of participants highlighted a lactate-TRAF1 relationship that could po-
tentially contribute to PTB.
Introduction
Preterm birth (PTB) is defined by the World Health Organisation as birth prior to 37 weeks of gestation
[1]. PTB complications are the leading cause of death in children under the age of five [2], but this multi-
factorial condition is not fully understood. Environmental factors are known to influence PTB and include
nutrition, maternal stress or infection [1]. Metabolomics is a field that monitors global metabolism of a
system, and this can be influenced by both environmental and genetic factors [3,4]. Clinical phenotypes
of non-iatrogenic spontaneous labour include spontaneous preterm birth (SPTB) and PPROM (preterm
premature rupture of membranes). To provide targeted SPTB preventative therapies, reliable biomarkers
of women with pregnancies destined to labour prematurely are required. This can be achieved by un-
derstanding the pathophysiology behind the initiation of early labour. Different regulation axis between
SPTB and PPROM have previously been suggested [5].
Many metabolomics studies applied less than 37 weeks of gestation as a cut-off for PTB [6,7] yet there is
an inverse relationship between gestation at birth and morbidity and mortality on the infant. Fortunately,
70% of preterm births are late preterm births (34–36+6) and have a low burden of morbidity [8]. However,
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this makes it difficult to study the preterm pregnancies most in need of prevention. Therefore, in the present study we
obtained cleaner phenotypes of PTB cases and defined outcomes as ≤ 34 weeks, in line with preterm birth prevention
services in the UK [9].
Recent PTB metabolomics studies [6,10,11] have utilised non-targeted analytical techniques such as nuclear mag-
netic resonance (NMR) to identify biomarkers in systemic fluids: cervicovaginal fluid, blood plasma and urine re-
spectively. Graca et al. [12], who applied mass-spectrometry, and Amabebe et al. [6] proposed several metabolite
predictors for PTB including acetate, lactate, phenylalanine and other amino acids. NMR is a highly sensitive and
reproducible method with high-throughput automated sample processing, which is advantageous for large sample
size studies screening biofluids [13–16].
Probabilistic neural network (PNN), a supervised machine learning method, can accurately classify metabolomic
data with respect to phenotype [17,18]. Rueedi et al. [19] applied metabolomics genome-wide association (MG-
WAS) method to gain an understanding of interactions between single-nucleotide polymorphisms (SNPs) and the
metabolome in serum samples. As metabolites are phenotype-driven, associating metabolites with genome-wide data
could enhance our knowledge of the pathways these metabolites are involved in. These, in addition to PNN, are novel
approaches to understanding the mechanism of early labour.
Metabolic profiling to distinguish the different clinical subtypes of PTB, preterm premature rupture of the mem-
branes (PPROM) and spontaneous preterm birth (SPTB) has not yet been reported. A non-invasive test of systematic
fluids could help screen and diagnose women susceptible to PTB in early pregnancy allowing for closer monitoring
and preventative treatment. This ’omics’ approach can also improve sensitivity and specificity of biomarkers, com-
pared with traditional clinical markers, by screening a population for multiple metabolites as reviewed by Monteiro
et al. [20].
The present study aimed to investigate the serum metabolome from a unique cohort of high-risk PTB women in
early pregnancy using untargeted 1-dimensional 1H (proton) NMR. An MGWAS approach was subsequently applied




Participants with singleton pregnancies, visiting between April 2012 to December 2017, were prospectively recruited
at 16 and 20 weeks of gestation at the Liverpool Women’s Hospital Preterm Birth Prevention Clinic. Research ethics
approval was obtained from the North West Research Ethics Committee, (REC reference: 11/NW/0720) and informed
consent was obtained from the participants. Clinical data on recruitment and delivery outcomes were collected and
followed up in this nested case–control study. Women who previously experienced preterm birth (≤ 34 weeks) and
subsequently delivered ≤ 37 weeks in the index pregnancy were categorised as high-risk (HTERM). Low-risk control
patients were parous women with all previous births at term and who delivered ≥ 39 weeks in the index pregnancy
(LTERM). Women who had spontaneous PTB ≤ 34+0 weeks gestation were reviewed and classified as a phenotype
of SPTB or PPROM. All births were phenotyped by authors A.C. and L.G., any disagreement in classification was
resolved by Z.A.
Participants were excluded if (i) they had a caregiver initiated preterm birth for other pregnancy specific pathology
(e.g. pre-eclampsia), (ii) intrauterine death occurred, (iii) had multiple pregnancies, (iv) underwent iatrogenic PTB
and (v) their spontaneous PTB occurred ≥ 34+0 weeks. Women from the low-risk control cohort were included if they
delivered ≥ 39 weeks (and excluded if they delivered < 39 weeks or received PTB prevention treatment [progesterone,
cervical pessary or cervical cerclage]). There is now ample evidence that many infants born at 38 weeks of gestation
or less experience an increase in neonatal mortality and even lifetime morbidity related to immaturity of one or more
organs when compared with infants born at 39 weeks or greater [21–25]. The arbitrary definition of a healthy term
birth being anything at or greater than 37 weeks does not correspond with functional maturity and as such may make
this definition redundant. For this reason, we, in agreement with others [26] believe defining term births as those
occurring at 39 weeks more appropriate.
This article will hereon refer to all non-iatrogenic spontaneous PTB as sPTB (the sub-categories of which are SPTB
and PPROM).
Sample collection
Samples were collected from all women who attended the clinic at 16 and 20 weeks of gestation. In addition, women
who only attended the clinic at either 16 or 20 weeks of gestation were included (7.8% of all women sampled). Maternal
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serum samples were collected in BD vacutainer® with clot activators and stored at room temperature (20– 25◦C) for
30 min. The samples were centrifuged at 3000 rpm at 4◦C for 10 min. Aliquots of 500 μl were prepared and stored at
−80◦C.
Sample preparation and NMR acquisition
Serum (500 μl) was thawed at room temperature and diluted with 500 μl of 200 mM phosphate (PO43−) buffer (pH
7.4) and deuterated water. Phosphate buffer was made using dibasic sodium phosphate (Na2HPO4, VWR Interna-
tional, US: Mr = 141.96) and monobasic sodium phosphate (NaH2PO4, Acros Organics Fisher Scientific, UK: Mr
= 119.98) in 20% 2H2O (Sigma, UK). In approximately 4.5% of samples, serum volume available was <500 μl, 200
μl of ddH2O was added to ensure a volume of >500 μl diluted serum (all samples were normalised including those
diluted to mitigate batch effects and the diluted samples were spread equitably between all four sample groups, rang-
ing between 2.4 and 5.6%). Samples were briefly vortexed and centrifuged at 21.5 rpm (∼21,500 g), 4◦C for 5 min.
Serum-buffer mix (600 μl) was transferred into 5 mm diameter NMR tubes for processing on the 600 MHz NMR
solution-state spectrometer Bruker Avance III system (Bruker, GmBH, Germany). A one-dimensional vendor sup-
plied (1D) Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence was applied to attenuate signals from high molecular
weight components [27]. Spectra were acquired at 37◦C, with 32 transients, 20 ppm spectral width with 4s inter-
scan delay – full parameter sets are available with the deposited dataset (MTBLS1990). Spectra were automatically
processed via standard vendor routines to ensure consistent Fourier transformation, window function and phasing
(Bruker macro apk0.noe). Spectra were aligned indirectly to Trimethylsilyl propionate via glucose anomeric doublet
(5.204 ppm). Quality control (QC) measures were performed manually according to ’The Metabolite Standards Ini-
tiative’ – MSI [28] briefly via measurement of the Line-Width Half Height (LWHH) of a representative peak – the
anomeric glucose located 5.244 ppm (< 3 Hz), ensuring a flat baseline for each sample spectrum, checking consistent
signal-to-noise ratio across spectra and ensuring good water suppression (i.e. water signal is narrow, and < 0.4 ppm
wide). Where the spectra failed QC the sample were repeated.
Metabolite annotation and identification
Metabolite annotation was determined through peak fitting of serum spectra initially using the metabolite library pro-
vided through Chenomx software v8.2 (Chenomx Inc., Canada) followed by comparison to in-house library spectra
for specific metabolites of interest (using 1D 1H and 2D 1H 13C HSQC where appropriate standard spectra acquired
on the same instruments under identical conditions). Peaks were converted to spectra ’bins’ by manual preparation
of a ’pattern file’ (a text file generated manually defining the left and right ppm boundaries for each individual peak
[or multiplet] in the spectrum). Peaks were then integrated over each bin boundary and divided by the width of each
bin using the software AMIX (Bruker, Coventry U.K.). The resultant bin or bucket table contained 145 individual
bins, 99 with metabolite specific annotation corresponding to 34 unique metabolites. A further 46 bins that were not
assigned to known metabolite signals. Metabolite annotations and identifications are defined as per ’The Metabolite
Standards Initiative’ – MSI [28], briefly metabolites annotated to an external library (i.e. Chenomx) were assigned to
’level 2 - annotation’ whereas metabolites with identities confirmed using two independent terms (such as 1H and
13C chemical shifts) from an in-house source were assigned to ’level 1 - identification’. Representative spectra can be
found in Supplementary Figure S1. Peak boundaries (pattern file) associated annotations and raw data are accessible
via open access repository MetaboLights [29], study ID: MTBLS1990.
NMR spectral bins analysis
Univariate statistical analysis was performed using R statistical computing environment [r-project.org]. Data were
first normalised per spectrum using Probabilistic Quotient Normalisation (PQN) [30] to offset any dilution effects
from the sample preparation. One-way ANOVA with Tukey’s HSD multiple testing was employed on the 145 vari-
able dataset using R packages ’car’ (Companion to Applied Regression). The four individual phenotypes (HTERM,
LTERM, SPTB and PPROM) were included in the analysis and a significance level of P < 0.05 was applied [31].
MetaboAnalyst was used to perform multivariate analysis with spectra normalised to the median and variables scaled
using the Pareto method. Principal component analysis (PCA) was employed to appraise spectra quality and ensure no
outliers were present and partial least squares discriminant analysis (PLS-DA) a widely used supervised, multivariate,
classification method in chemometrics. PLS-DA classification, with 10-fold cross-validation to evaluate the predictive
model, using R packages ’pls’ [32] and ’caret’ [33]. The Q2 value describes the cross-validated sum of squares (R2),
which is provided with the model prediction accuracy score by MetaboAnalyst [34]. The PNN algorithm was executed
on all 145 metabolite bins per timepoint using a predictive modelling software: DTREG (https://www.dtreg.com/)
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[35]. Leave-one-out cross-validation (LOOCV) was applied and the AUC values obtained for each gestation time-
point. For this analysis, the phenotypes were combined: sPTB cases (SPTB and PPROM) and controls (HTERM and
LTERM).
DNA preparation and genome-wide screening
DNA was extracted from whole blood using the Chemagenic Magnetic Separation Module I (Auto Q Biosciences
Ltd, U.K.) and were processed on the Applied Biosystems™ UK Biobank Axiom™ array (Thermo Fisher Scientific)
for genome-wide screening by the Oxford Genomics Centre at the Wellcome Centre for Human Genetics.
Genome-wide association (GWAS) data quality control and imputation
Genotypes acquired from the UK Biobank Axiom™ array (Thermo Fisher) were analysed using PLINK v1.9 software
[36]. Data quality control (QC) was carried out using the methods described by Anderson et al. [37] and Marees
et al. [38]. QC steps involved removing SNPs with low genotype call rate, or high proportion of SNP missingness;
checking for gender discrepancies based on heterozygosity in chromosome X; excluding SNPs with low minor allele
frequency (MAF) of < 1% and removing SNPs deviating from Hardy–Weinberg Equilibrium (HWE) at P ≤ 1 × 10−6.
Samples with high or low heterozygosity rates (+− 3 standard deviations from the mean) or close relatedness (pi-hat
score > 0.2) were excluded. Individuals not genetically assigned to European ancestry (CEU) population based on the
HapMap data were also excluded from the study [39,40]. A total of 618,283 SNPs were uploaded on to the Michigan
Imputation Server for phasing chromosome 1 to 22 using Eagle v2.3 and imputation (using the minimac3 algorithm)
against HRC r1.1 2016 panel [41,42]. Post-imputation QC steps involved removing variants with R2 < 0.3 [43] and
MAF = 0 (or < 1%).
MGWAS and SNP annotation
Inverse-rank normalisation was applied to all the metabolite bin relative peak abundances. Frequentist association
test of the GWAS SNP data and the NMR metabolite bins as a continuous outcome was completed using SNPTEST
v2.5 [44–46]. Manhattan plots were generated using qqman R package [47]. Total number of samples included at
week 16, n=251 and at week 20, n=265.
SNPs above suggestive threshold of 1 × 10−5 were selected from each MGWAS analysis and further investigated for
functional annotation of the SNPs and expression quantitative trait locus (eQTL) FUMA GWAS (Functional Mapping
and Annotation of Genome-Wide Association Studies) SNP2GENE [48].
eQTL mapping and enrichment analysis
Lead SNPs were defined as P ≤ 1 × 10−5 using 1000Genomes phase 3 European population [49,50] as the reference
panel, GTEx v8 database tissue types for eQTL mapping and eQTL FDR P < 0.05 cut-off. For gene set enrichment
analysis and annotation in biological context, SNP2GENE results of genome-wide significant SNPs were submitted
to FUMA GENE2FUNC, using GTEx v8 tissue types.
Results
Participants
A total of 567 women were recruited and categorised into delivery phenotypes or excluded from the study (Figure
1A).
Table 1 summarises the participant demographics included in metabolomics analyses, after three samples were
excluded at week 20, due to EDTA contamination (Figure 1B). Recruits missing visits at either timepoint remained
in the analyses as a single sample.
Metabolomics findings
ANOVA, with Tukey’s HSD of the four individual phenotypes, showed 22 metabolite bins at week 16 to be significant
(P < 0.05) mainly between the control groups LTERM and HTERM (Table 2). Four metabolite bins were significant
(Tukey’s post-hoc P < 0.05) for SPTB-LTERM comparison: these were unknown (3.32 ppm), unknown (7.28 ppm),
unknown (4.40 ppm) and glucarate (4.14 ppm). When comparing PPROM-LTERM, only three bins were significant
(P < 0.05): unknown (3.32 ppm), unknown (3.28 ppm) and unknown (3.30 ppm).
ANOVA of week 20 metabolite bins highlighted 34 significant bins (Tukey’s post-hoc P < 0.05), 12 more than week
16 (Table 3). SPTB-LTERM showed 15 metabolite bins were significant at P < 0.05, 11 bins for PPROM-LTERM and
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Figure 1. Schematic of pregnant participants recruited to the Liverpool preterm birth study cohort and the number of
samples acquired
(A) Final number of women for each phenotypic group included in the analyses. (B) Serum samples were collected from participants
at 16 and/or 20 weeks of gestation (of those included in the study analyses) for metabolomics. (C) Whole blood-extracted DNA was
collected for genotyping (for women included in the study analyses); GWAS, genome-wide association study; HTERM, high-risk
term births; LTERM, low-risk term births; NMR, nuclear magnetic resonance; PPROM, preterm premature rupture of membranes;
sPTB, spontaneous preterm birth (including PPROM and SPTB); SPTB, spontaneous preterm birth.
1 bin (unknown [7.28 ppm], Tukey’s post-hoc P = 0.036) for SPTB-HTERM. Unknown (3.32 ppm) and unknown
(3.28 ppm) were also significant in week 20 similarly to week 16, warranting further investigation. More annotated
metabolites were identified at week 20, such as 2-hydroxybutyrate (4.02 ppm) (P = 2.16E-05) and creatinine (4.06
ppm) (P = 1.63E-04). More LTERM and SPTB/PPROM comparisons were significant (P < 0.05), including lactate
and glucarate (4.13 ppm), lactate (4.11 ppm) and lactate (1.33 ppm).
Multivariate supervised discriminant analysis demonstrated no clear separation of clusters of the four different
clinical groups and poor prediction. At week 16, PLS-DA yielded an R2 = 0.034, Q2 = 0.014, 3-components (Sup-
plementary Figure S2). Similarly, at week 20, PLS-DA model yielded R2 = 0.06, Q2 = 0.007, 3-components (Supple-
mentary Figure S3).
Predictive modelling using probabilistic neural networks
As PLS-DA did not show clear discrimination between SPTB and PPROM, PNN analysis of all the metabolite bins
was conducted between sPTB cases combined (PPROM and SPTB) and controls at week 16 gestation and showed
moderate predictive power AUC = 0.77 (LOOCV) (Supplementary Table S1). Unknown (3.32 ppm) bin had the
highest rank in the week 16 prediction model, which is consistent with the univariate analyses as shown in the log
fold change diagram [51] (Tables 2 and 3; Figure 2A).
PNN analysis at week 20 of gestation obtained stronger predictive power with AUC = 0.89 than week 16 (Supple-
mentary Table S1). Unknown (7.28 ppm) was another top hit followed by creatinine (4.06 ppm) as with the ANOVA
results. Further matches with ANOVA at week 20 were observed for lactate and glucarate (4.13 ppm), lactate (4.11
ppm) and phenylalanine (7.43 ppm), which also scored highly in the PNN model (Figure 2B).
MGWAS and SNP annotation results
A total of 251 women at week 16 and 265 women at week 20 had both GWAS and NMR data available and were
included in MGWAS analyses (Figure 1C). Of 290 MGWAS analyses at both timepoints, the lowest P-value and
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Table 1 Baseline demographics of PTB metabolomics participants at week 16 and 20 of gestation







































NA 2 (1.1%) 1 (0.9%) 1 (5.6%) 0 (0.0%) 2 (1.2%) 1 (0.9%) 0 (0.0%) 0 (0.0%)
No 163 (89.1%) 82 (75.9%) 12 (66.7%) 16 (80.0%) 154 (89.5%) 85 (78.7%) 12 (75.0%) 18 (81.8%)
Yes 18 (9.8%) 25 (23.1%) 5 (27.8%) 4 (20.0%) 16 (9.3%) 22 (20.4%) 4 (25.0%) 4 (18.2%)
Ethnicity 0.2513 0.1503
White 177 (96.7%) 99 (91.7%) 17 (94.4%) 20 (100.0%) 166 (96.5%) 99 (91.7%) 14 (87.5%) 22 (100.0%)
Black 3 (1.6%) 8 (7.4%) 1 (5.6%) 0 (0.0%) 3 (1.7%) 7 (6.5%) 1 (6.2%) 0 (0.0%)
Other 2 (1.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
NA 1 (0.5%) 1 (0.9%) 0 (0.0%) 0 (0.0%) 1 (0.6%) 2 (1.9%) 1 (6.2%) 0 (0.0%)
No. of prior SPTB/PPROM <34 weeks
0 183 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 172 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
1 0 (0.0%) 102 (94.4%) 13 (72.2%) 14 (70.0%) 0 (0.0%) 102 (94.4%) 12 (75.0%) 16 (72.7%)
2 0 (0.0%) 6 (5.6%) 4 (22.2%) 5 (25.0%) 0 (0.0%) 6 (5.6%) 3 (18.8%) 5 (22.7%)
3 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
4 0 (0.0%) 0 (0.0%) 1 (5.6%) 1 (5.0%) 0 (0.0%) 0 (0.0%) 1 (6.2%) 1 (4.5%)
Previous significant cervical surgery 0.0323 0.1353
No 180 (98.4%) 108 (100.0%) 16 (88.9%) 20 (100.0%) 169 (98.3%) 108 (100.0%) 15 (93.8%) 22 (100.0%)
Yes4 3 (1.6%) 0 (0.0%) 2 (11.1%) 0 (0.0%) 3 (1.7%) 0 (0.0%) 1 (6.2%) 0 (0.0%)
Gestation at sampling (days) <0.0012 <0.0012
Median
(IQR)
117.0 (5) 114.0 (5) 113.5 (5) 113.5 (5.2) 144.5 (5) 142.0 (5) 143.5 (6.5) 143.0 (3.8)
Participant serum samples collected at these timepoints, included in the analyses, are shown in these final numbers.
1Linear Model ANOVA.
2Kruskal–Wallis rank sum test.
3Fisher’s Exact Test for Count Data.
4Previous large loop excision of the transformation zone (LLETZ), multiple LLETZ or Knife Cone Biopsy.
strongest genetic association with relative peak intensity was observed at week 16 for phenylalanine (7.43 ppm) with
rs117209391 (a non-coding RNA, see Supplementary Table S2) reaching genome-wide significance (Figure 3). Several
signals observed across the remaining MGWAS analyses did not reach the genome-wide significance threshold.
Genome-wide significant (P < 5 × 10−8) SNPs in nine metabolite bins were identified, including phenylalanine
(7.43 ppm), 2-hydroxybutyrate (0.92 ppm), proline (3.37 ppm), lactate (4.11 ppm), unknown (7.06 ppm) and proline
(2.33 ppm) at week 16 and glucose (3.77 ppm), myoinositol (3.58 ppm) and lactate (4.11 ppm) at week 20 (Supple-
mentary Table S2).
FUMA SNP annotation of MGWAS results identified one exonic SNP in unknown (5.39 ppm), week 16 metabolite
bin (chr:bp 20:19941367, rs45481396, P = 1.85E-06), the remaining SNPs were in non-coding regions. Rs45481396,
located in a protein coding gene RIN2 (Ras and Rab Interactor 2), is involved in membrane trafficking processes.
eQTL and enrichment analysis
Cis-eQTL mapping of genome-wide significant SNPs identified one gene, TRAF1 (tumour necrosis factor receptor
associated factor 1) for lactate (4.11 ppm) at week 16 (Supplementary Table S2). This suggests that the non-coding SNP
detected in the week 16 lactate (4.11 ppm) MGWAS (rs7867041, intergenic RP11-360A18.1, P = 3.08 × 10−8) could
influence gene expression of the neighbouring gene, TRAF1. TRAF1 is involved in multiple immune/inflammatory
related pathways such as TNF signalling and NF-kappa B signalling pathway (including interleukins) (KEGG ID:
04064) as recorded in the KEGG database [52].
However, gene set enrichment analysis with the GTEx database did not show any differential expression in re-
productive or pregnancy-associated tissues. Contrary to this, enrichment analysis of lactate (4.11 ppm) at week 20,
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Table 2 Summary of 22 significant metabolite bins (P<0.05) at week 16 of gestation shown by ANOVA with Tukey’s HSD
Metabolite bin (chemical shift in
ppm) P-value Tukey’s HSD P-adjusted
Unknown (3.32) 1.90E-07 LTERM-HTERM 2.67E-05
SPTB-LTERM 0.002
PPROM-LTERM 0.003
Unknown (3.28) 2.30E-04 PPROM-LTERM 0.010
LTERM-HTERM 0.012
Unknown (7.28) 4.88E-04 SPTB-LTERM 0.003
Unknown (3.3) 0.001 PPROM-LTERM 0.013
LTERM-HTERM 0.026
Unknown (4.40) 0.005 SPTB-LTERM 0.019
Glucarate (4.14) 0.005 SPTB-LTERM 0.011
Phenylalanine (7.43) 0.005 NA NA
Tyrosine (6.90) 0.006 LTERM-HTERM 0.020
Creatine40 (3.93) 0.01 LTERM-HTERM 0.013
Unknown (1.92) 0.011 LTERM-HTERM 0.010
Acetate (1.92) 0.011 LTERM-HTERM 0.009
Unknown (3.92) 0.013 LTERM-HTERM 0.010
Glucose (3.91) 0.014 LTERM-HTERM 0.007
Choline (3.19) 0.019 LTERM-HTERM 0.020
NDMA (3.15) 0.022 LTERM-HTERM 0.021
Glucose (3.52) 0.027 LTERM-HTERM 0.015
Mobile lipids (1.23) 0.028 LTERM-HTERM 0.035
2-Hydroxybutyrate (4.02) 0.039 NA NA
Glucose (3.78) 0.043 LTERM-HTERM 0.027
Unknown (3.63) 0.044 LTERM-HTERM 0.033
Unknown (3.56) 0.048 NA NA
A total of 12 bins were annotated metabolites and 10 were unknown. HTERM (n=108), LTERM (n=183), PPROM (n=18) and SPTB (n= 20).
NA = the individual outcome comparison did not meet the P≤0.05 cut-off.
demonstrated that gene sets were upregulated in breast tissue (FDR, P = 0.039) in GTEx (Supplementary Figure S4).
This was also true for uterus (P = 0.032), but this was not significant after FDR adjustment (FDR, P = 0.97).
Discussion
Significant differences (P < 0.05) determined between term and sPTB in the metabolite profiles include phenylalanine
(7.43 ppm) and acetate (1.92 ppm) at week 16 and creatinine (4.06 ppm), lactate and glucarate (4.13 ppm), lactate
(4.11 ppm) and lactate (1.33 ppm) at week 20 between controls and sPTB cases (Tables 1 and 2; Figure 2). PNN also
showed strong contribution of these metabolites, particularly at week 20 of gestation (AUC = 0.89).
Acetate and lactate were detected in cervicovaginal fluid, using NMR, in preterm symptomatic pregnant women
at 20–22 weeks of gestation [6]. Phenylalanine (and leucine/isoleucine, histidine, and valine) were found in amniotic
fluid, at 16–21 weeks gestation, investigated using mass-spectrometry [12]. Our cohort, comprised of sPTB cases and
healthy controls at two early gestational timepoints, yielded similar results as shown by ANOVA and PNN.
There are several strengths of our study: (1) clinically well-defined phenotype in early pregnancy of a prospective
cohort of women with pre-defined inclusion/exclusion criteria and clearly defined control groups: first, women at
high-risk of sPTB with a history of sPTB in previous pregnancy; second, women at low-risk of sPTB with previous
term birth; (2) inclusion of sPTB cases only if ≤ 34 weeks at birth; (3) availability of multi-omic data in the same
individual at two timepoints and the novelty in analytical approaches including PNN; (4) rigorous quality control of
clinical, experimental and analytical data.
One novel aspect of the present study was the combination of metabolomics and genotype data from the same
participants in the sPTB cohort, which were applied in MGWAS association analyses. Identification of SNP associ-
ations with each metabolite bin was a non-standard approach implemented to gain insights of molecular pathways
contributing to sPTB phenotypes. A strong genetic association of phenylalanine (7.43 ppm) and lactate (4.11 ppm)
bins at week 16 and lactate (4.11 ppm) at week 20 with the sPTB cohort genome-wide data were determined (Figure
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Table 3 Summary of 34 significant metabolite bins at week 20 of gestation with P<0.05 ANOVA with Tukey’s HSD
Metabolite bin (chemical
shift in ppm) Annotation level (MSI) P-value Tukey’s HSD P-adjusted
Unknown (3.32) 4 4.77E-08 LTERM-HTERM 7.27E-05
PPROM-LTERM 1.20E-04
SPTB-LTERM 0.002
2-Hydroxybutyrate (4.02) 2 2.16E-05 PPROM-LTERM 0.001
LTERM-HTERM 0.007
SPTB-LTERM 0.024
Unknown (7.28) 4 5.12E-05 SPTB-LTERM 1.15E-04
LTERM-HTERM 0.025
SPTB-HTERM 0.036
Creatinine (4.06) 1 1.63E-04 SPTB-LTERM 0.002
PPROM-LTERM 0.017
Glucarate and myoinositol (4.04) 2 and 1 2.51E-04 PPROM-LTERM 0.012
SPTB-LTERM 0.022
LTERM-HTERM 0.022
Unknown (3.28) 4 0.003 PPROM-LTERM 0.011
Lactate and glucarate (4.13) 1 and 2 0.004 PPROM-LTERM 0.033
SPTB-LTERM 0.035
Lactate (1.33) 1 0.004 SPTB-LTERM 0.043
PPROM-LTERM 0.044
Lactate (4.11) 1 0.004 PPROM-LTERM 0.038
SPTB-LTERM 0.048
Unknown (4.40) 4 0.005 PPROM-LTERM 0.026
Propylene-glycol (1.15) 1 0.005 PPROM-LTERM 0.002
PPROM-HTERM 0.017
Mobile lipids (1.23) 3 0.01 LTERM-HTERM 0.010
Choline (3.19) 2 0.011 LTERM-HTERM 0.026
2-Hydroxyvalerate (4.07) 2 0.012 SPTB-LTERM 0.030
Proline (2.33) 1 0.012 SPTB-LTERM 0.046
NDMA (3.15) 2 0.013 LTERM-HTERM 0.018
3-Hydroxybutyrate (4.16) 2 0.013 SPTB-LTERM 0.014
Myoinositol (3.58) 1 0.013 SPTB-LTERM 0.027
3-Hydroxybutyrate (1.20) 2 0.015 LTERM-HTERM 0.036
Glucarate (4.14) 2 0.016 SPTB-LTERM 0.022
Acetoacetate (2.23) 1 0.017 SPTB-LTERM 0.043
Unknown (1.09) 4 0.017 LTERM-HTERM 0.047
Glutamate (2.26) 1 0.018 NA NA
2-Hydroxyvalerate and arginine
(1.62)
2 and 1 0.02 NA NA
Unknown (3.34) 4 0.021 NA NA
Mobile lipids (1.29) 3 0.03 NA NA
Unknown (1.41) 4 0.031 NA NA
Unknown (4.46) 4 0.032 NA NA
Unknown (1.54) 4 0.032 NA NA
3-Hydroxybutyrate (2.42) 2 0.039 SPTB-LTERM 0.025
Mannose (5.19) 1 0.046 NA NA
Glutamate (2.48) 1 0.047 LTERM-HTERM 0.035
Phenylalanine (7.43) 1 0.049 NA NA
Unknown (2.78) 4 0.049 NA NA
Of these bins, 24 were annotated metabolites and 10 were unknown [28]. HTERM (n=108), LTERM (n=172), PPROM (n=16) and SPTB (n=22).
NA = the individual outcome comparison is borderline P > 0.05 and therefore does not meet the P ≤ 0.05 cut-off.
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Figure 2. Log fold change diagrams of 1H NMR significant metabolite bins identified from univariate and multivariate
analyses
Individual pregnancy outcome groups were compared, where LTERM was the control group at (A) week 16 of gestation (11 metabo-
lite bins) (N=329) and (B) week 20 of gestation (14 metabolite bins) (N=318). Red indicates positive fold change and blue for negative
fold change with respect to LTERM. Plots were generated using ’ggplot2’ R package [51] and R script developed by R. Grosman,
2017 (University of Liverpool).
3). Due to low prevalence of these SNPs in this cohort, the outcomes could not be associated with the SNPs; however,
meta-analysis with similar cohorts could allow for a robust comparison.
SNP annotation of the known bins indicated non-coding gene regions. FUMA cis-eQTL analysis identified neigh-
bouring gene, TRAF1, in association with the leading SNP significant (P < 5 × 10−8) in lactate (4.11 ppm) metabolite
bin at week 16 of gestation. TRAF1 is related to similar signalling pathways involving NF-κβ, of which NFKB1 gene
was previously reported in a literature-informed analysis by Bacelis et al. [53] and reviewed by MacIntyre et al. [54]
as a potential biomarker of PTB. TRAF1 forms a heterodimeric complex with TRAF2, which was associated with
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 3. Manhattan plot of phenylalanine (7.43 ppm) metabolite bin MGWAS analysis at week 16 of gestation
Spectra were obtained from 1H NMR of preterm birth maternal serum (N=251). Chromosome 11 SNP rs117209391 (P = 9.96 ×
10−9), reached genome-wide significance (P < 5 × 10−8, red line) . A strong association was observed between phenylalanine
(7.43 ppm) metabolite peak intensity and genome-wide data. This plot was generated using R package, qqman [47].
PTB [55]. The complex acts as a mediator of anti-apoptotic signals from TNF receptors [55], which also indicates the
role of the TRAF1 gene in the inflammatory pathway. Other studies have indicated the role of innate immune cells in
producing lactate when activated by an inflammation response [56,57]. This suggests that TRAF1 could be part of the
activation of inflammation processes, which in turn activate immune cells that secretes lactate detectable in serum.
This could explain the lactate differences between sPTB cases and controls identified by ANOVA and PNN. Further
analysis is required to confirm this hypothesis, however, raised lactate indicating disease other than a non-genetic
biological response (e.g. sepsis and cardiac arrest [58]) is highly unlikely as these women presented well to their out-
patient clinical appointments and were reviewed by obstetricians trained in the identification of disease in pregnancy.
Gene set enrichment analysis with GTEx database highlighted lactate at week 20 elevated in cervix tissue (Supple-
mentary Figure S4) has been previously reported in the literature [6]. Our enrichment analysis suggested that lactate
was elevated in breast tissue, but there is no association with preterm birth in the current literature.
Some limitations of the study include the variability in metabolic profiles in NMR studies on biofluids caused by
exogenous substances or environmental factors, such as drugs or food intake. This was taken into consideration in
the present study by following up the univariate analysis with PNN. This unbiased modelling approach confirmed
contribution of similar metabolites as found in the ANOVA.
Despite reporting on one of the largest prospective recruitments of sPTB < 34 weeks cases by targeting a high-risk
population, the number of overall cases were low especially when sub-classified into SPTB and PPROM. However,
the study design allowed univariate and multivariate analyses at two timepoints and with multiple omics datasets in
this phenotypically well-defined cohort. ANOVA identified many differences between LTERM (healthy controls) and
sPTB cases, which could contribute to the preterm phenotypes. However, the metabolic profile of HTERM women
could share similarities with those who experience a recurrent sPTB, as all high-risk participants previously experi-
enced sPTB, unlike LTERM. PLS-DA could not distinguish between the four phenotype groups, potentially due to
the low numbers; however, combining sPTB cases and controls for PNN analysis demonstrated differences between
cases and controls, whilst displaying predictive power.
There are several unknown metabolites associated with ANOVA and PNN. Further work is underway to attempt
to identify these unknown metabolites. Proteomics data for this cohort are presently being gathered. Analysis of this
data will provide a mechanistic insight of how the genes identified may influence the production of metabolites, which
could influence the pathophysiology of PTB.
To our knowledge, this is the first study to have used NMR metabolic profiling of a clearly defined cohort of high
and low-risk sPTB participants. Another unique aspect was the collection of multiple omics data from the same
10 © 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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participants, which highlighted the potential role of several metabolites in the initiation of early labour. This pheno-
typically well-defined cohort of patient samples provides invaluable resources for future studies to be undertaken to
enhance our understanding of the sPTB pathophysiology.
Clinical perspectives
• Spontaneous preterm births (PTB) are a major cause of infant morbidity and mortality worldwide.
This condition remains poorly understood and there is a need for biomarkers that can aid patient
stratification and predict phenotypes of spontaneous preterm birth.
• The present study demonstrated that metabolite signatures differ between spontaneous PTB cases
and term controls. Further analysis of metabolomic data with genomic data from the same partici-
pants indicate the potential role of the inflammation pathway via the TRAF1 gene.
• This is the first study to recruit and phenotype pregnant women for multi-omic investigation at
high-risk and low-risk of spontaneous preterm birth. Further validation of these multi-omic biomarkers
may allow screening for spontaneous preterm birth risk in asymptomatic women in early pregnancy.
Data Availability
Metabolomic analysis data are available in the open-access repository MetaboLights, study ID: MTBLS1990.
Competing Interests
The authors declare that there are no competing interests associated with the manuscript.
Funding
The Harris-Wellbeing Research Centre was funded by the Wellbeing of Women charity, London, for this research.
Open Access
Open access for this article was enabled by the participation of University of Liverpool in an all-inclusive Read & Publish pilot with
Portland Press and the Biochemical Society under a transformative agreement with JISC.
CRediT Author Contribution
Juhi Gupta: Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing—original draft,
Writing—review and editing. Angharad Care: Conceptualization, Resources, Supervision, Funding acquisition, Investigation,
Methodology, Writing—original draft, Writing—review and editing. Laura Goodfellow: Conceptualization, Resources, Super-
vision, Methodology, Writing—original draft. Zarko Alfirevic: Conceptualization, Resources, Funding acquisition, Methodol-
ogy, Writing—review and editing. Lu-Yun Lian: Resources, Investigation, Methodology, Writing—review and editing. Bertram
Müller-Myhsok: Conceptualization, Resources, Supervision, Validation, Investigation, Methodology, Writing—original draft,
Writing—review and editing. Ana Alfirevic: Conceptualization, Supervision, Funding acquisition, Methodology, Writing—original
draft, Writing—review and editing. Marie M. Phelan: Conceptualization, Resources, Data curation, Formal analysis, Supervision,
Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing.
Acknowledgements
We would like to acknowledge the study participants, the researchers (including Daniel Thomas and Raven Chandramohan from
Ngee Ann Polytechnic) at the NMR Centre for Structural Biology for assisting with NMR data acquisition and preparation for analy-
sis and the Oxford Genomics Centre (Wellcome Centre for Human Genetics) for processing our DNA samples on Biobank Axiom™
array (Thermo Fisher). We would also like to acknowledge the study participants and our research funders, Wellbeing of Women
charity, London.
Abbreviations
ANOVA, analysis of variance; AUC, area under the curve; EQTL, expression quantitative trait loci; GTEx, Genotype-Tissue Ex-
pression Project; HTERM, high-risk term; LLETZ, large loop excision of the transformation zone; LOOCV, leave-one-out cross
validation; LTERM, low-risk term; MGWAS, metabolomics genome-wide association; NMR, nuclear magnetic resonance; PNN,
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
Attribution License 4.0 (CC BY).
11
Bioscience Reports (2021) 41 BSR20210759
https://doi.org/10.1042/BSR20210759
probabilistic neural network; PPROM, preterm premature rupture of membranes; PTB, preterm birth; SNP, single-nucleotide
polymorphism; SPTB, spontaneous preterm birth.
References
1 Menon, R. (2008) Spontaneous preterm birth, a clinical dilemma: etiologic, pathophysiologic and genetic heterogeneities and racial disparity. Acta
Obstet. Gynecol. Scand. 87, 590–600, https://doi.org/10.1080/00016340802005126
2 Liu, L., Oza, S., Hogan, D., Perin, J., Rudan, I., Lawn, J.E. et al. (2015) Global, regional, and national causes of child mortality in 2000–13, with
projections to inform post-2015 priorities: an updated systematic analysis. Lancet North Am. Ed. 385, 430–440,
https://doi.org/10.1016/S0140-6736(14)61698-6
3 Li, J., Lu, Y.P., Reichetzeder, C., Kalk, P., Kleuser, B., Adamski, J. et al. (2016) Maternal PCaaC38:6 is associated with preterm birth - a risk factor for
early and late adverse outcome of the offspring. Kidney Blood Press. Res. 41, 250–257, https://doi.org/10.1159/000443428
4 Lindon, J., Nicholson, J., Holmes, E. and Everett, J. (2000) Metabonomics: metabolic processes studied by NMR spectroscopy of biofluids. Concepts
Magn. Reson. 12, 289–320, https://doi.org/10.1002/1099-0534(2000)12:5%3c289::AID-CMR3%3e3.0.CO;2-W
5 Capece, A., Vasieva, O., Meher, S., Alfirevic, Z. and Alfirevic, A. (2014) Pathway analysis of genetic factors associated with spontaneous preterm birth
and pre-labor preterm rupture of membranes. PLoS ONE 9, e108578, https://doi.org/10.1371/journal.pone.0108578
6 Amabebe, E., Reynolds, S., Stern, V.L., Parker, J.L., Stafford, G.P., Paley, M.N. et al. (2016) Identifying metabolite markers for preterm birth in
cervicovaginal fluid by magnetic resonance spectroscopy. Metabolomics 12, 67, https://doi.org/10.1007/s11306-016-0985-x
7 Virgiliou, C., Gika, H.G., Witting, M., Bletsou, A.A., Athanasiadis, A., Zafrakas, M. et al. (2017) Amniotic fluid and maternal serum metabolic signatures
in the second trimester associated with preterm delivery. J. Proteome Res. 16, 898–910, https://doi.org/10.1021/acs.jproteome.6b00845
8 Engle, W.A., Tomashek, K.M., Wallman, C. and the Committee on Fetus and Newborn (2007) “Late-preterm” infants: a population at risk. Pediatrics
120, 1390–1401, https://doi.org/10.1542/peds.2007-2952
9 NHS England (2019) Saving Babies’ Lives Care Bundle Version 2.
https://www.england.nhs.uk/publication/saving-babies-lives-version-two-a-care-bundle-for-reducing-perinatal-mortality/ [Accessed: 19/03/2021]
10 Diaz, S.O., Pinto, J., Graca, G., Duarte, I.F., Barros, A.S., Galhano, E. et al. (2011) Metabolic biomarkers of prenatal disorders: an exploratory NMR
metabonomics study of second trimester maternal urine and blood plasma. J. Proteome Res. 10, 3732–3742, https://doi.org/10.1021/pr200352m
11 Maitre, L., Fthenou, E., Athersuch, T., Coen, M., Toledano, M.B., Holmes, E. et al. (2014) Urinary metabolic profiles in early pregnancy are associated
with preterm birth and fetal growth restriction in the Rhea mother-child cohort study. BMC MEDICINE 12, https://doi.org/10.1186/1741-7015-12-110
12 Graca, G., Goodfellow, B.J., Barros, A.S., Diaz, S., Duarte, I.F., Spagou, K. et al. (2012) UPLC-MS metabolic profiling of second trimester amniotic fluid
and maternal urine and comparison with NMR spectral profiling for the identification of pregnancy disorder biomarkers. Mol. Biosyst. 8, 1243–1254,
https://doi.org/10.1039/c2mb05424h
13 Dettmer, K., Aronov, P.A. and Hammock, B.D. (2007) Mass spectrometry-based metabolomics. Mass Spectrom. Rev. 26, 51–78,
https://doi.org/10.1002/mas.20108
14 Dunn, W.B., Bailey, N.J. and Johnson, H.E. (2005) Measuring the metabolome: current analytical technologies. Analyst 130, 606–625,
https://doi.org/10.1039/b418288j
15 Goodacre, R., Vaidyanathan, S., Dunn, W.B., Harrigan, G.G. and Kell, D.B. (2004) Metabolomics by numbers: acquiring and understanding global
metabolite data. Trends Biotechnol. 22, 245–252, https://doi.org/10.1016/j.tibtech.2004.03.007
16 Orczyk-Pawilowicz, M., Jawien, E., Deja, S., Hirnle, L., Zabek, A. and Mlynarz, P. (2016) Metabolomics of Human Amniotic Fluid and Maternal Plasma
during Normal Pregnancy. PLoS ONE 11, e0152740, https://doi.org/10.1371/journal.pone.0152740
17 Holmes, E., Nicholson, J.K. and Tranter, G. (2001) Metabonomic characterization of genetic variations in toxicological and metabolic responses using
probabilistic neural networks. Chem. Res. Toxicol. 14, 182–191, https://doi.org/10.1021/tx000158x
18 Specht, D.F. (1990) Probabilistic neural networks. Neural Netw. 3, 109–118, https://doi.org/10.1016/0893-6080(90)90049-Q
19 Rueedi, R., Mallol, R., Raffler, J., Lamparter, D., Friedrich, N., Vollenweider, P. et al. (2017) Metabomatching: using genetic association to identify
metabolites in proton NMR spectroscopy. PLoS Comput. Biol. 13, e1005839, https://doi.org/10.1371/journal.pcbi.1005839
20 Monteiro, M.S., Carvalho, M., Bastos, M.L. and Guedes de Pinho, P. (2013) Metabolomics analysis for biomarker discovery: advances and challenges.
Curr. Med. Chem. 20, 257–271, https://doi.org/10.2174/092986713804806621
21 Tita, A.T.N., Landon, M.B., Spong, C.Y., Lai, Y., Leveno, K.J., Varner, M.W. et al. (2009) Timing of elective cesarean delivery at term and neonatal
outcomes. N. Engl. J. Med. 360, 111–120, https://doi.org/10.1056/NEJMoa0803267
22 Sengupta, S., Carrion, V., Shelton, J., Wynn, R.J., Ryan, R.M., Singhal, K. et al. (2013) Adverse neonatal outcomes associated with early-term birth.
JAMA Pediatr. 167, 1053–1059, https://doi.org/10.1001/jamapediatrics.2013.2581
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